Omeros Co. (NASDAQ:OMER) has earned a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $40.60.
A number of brokerages have commented on OMER. Zacks Investment Research lowered Omeros from a “buy” rating to a “hold” rating in a report on Friday, September 10th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Omeros in a research report on Tuesday, September 7th. Finally, WBB Securities upped their target price on Omeros from $75.00 to $100.00 and gave the company a “strong-buy” rating in a research report on Friday, June 18th.
Shares of OMER stock traded up $0.22 during trading on Friday, reaching $15.98. 790,316 shares of the company’s stock were exchanged, compared to its average volume of 589,739. The stock has a market capitalization of $998.69 million, a PE ratio of -6.98 and a beta of 1.12. Omeros has a twelve month low of $9.25 and a twelve month high of $23.85. The firm’s fifty day moving average price is $14.99 and its 200-day moving average price is $16.40.
Several hedge funds have recently made changes to their positions in OMER. Handelsbanken Fonder AB bought a new stake in shares of Omeros during the 1st quarter worth $267,000. Outfitter Financial LLC bought a new position in Omeros in the first quarter valued at about $580,000. Blueshift Asset Management LLC bought a new position in Omeros in the first quarter valued at about $227,000. Brighton Jones LLC raised its position in Omeros by 81.1% in the first quarter. Brighton Jones LLC now owns 96,303 shares of the biopharmaceutical company’s stock valued at $1,714,000 after purchasing an additional 43,125 shares during the last quarter. Finally, IndexIQ Advisors LLC bought a new position in Omeros in the first quarter valued at about $402,000. Institutional investors and hedge funds own 51.84% of the company’s stock.
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
See Also: Fiduciary
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.